Viking Therapeutics

Viking Therapeutics

Yahoo Finance • 22 hours ago

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

High-stakes clinical trials define the 2026 landscape for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to revolutionize patient care while navigating the complex path toward regulatory approval. Dy... Full story

Yahoo Finance • 3 days ago

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Vikin... Full story

Yahoo Finance • 4 days ago

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

GLP-1 drugs are proving helpful for many conditions, not just weight loss. In studies, they have shown they can reduce cardiovascular risk, sleep apnea, and even curb addictions. They have the potential to truly transform healthcare, and t... Full story

Yahoo Finance • 4 days ago

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Quick Read AbbVie (ABBV) proved big pharma will pay up for late-stage immunology with the Apogee deal, reigniting M&A speculation across the biotech sector. Syndax (SNDX) earns the top takeover ranking with two FDA-approved drugs, 224% re... Full story

Yahoo Finance • 4 days ago

Is Viking Therapeutics Stock a No-Brainer Buy Below $35?

Key Points Viking Therapeutics is running phase 3 studies for its leading anti-obesity candidate. Its shares could soar from current levels, provided everything goes according to plan. 10 stocks we like better than Viking Therapeutics ›... Full story

Yahoo Finance • 10 days ago

Viking Therapeutics (VKTX) Offers Potential With VK2735 Market Opportunity

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best mid-cap stocks that could double your money. On May 28, Lake Street assigned a Buy rating to Viking Therapeutics Inc. (NASDAQ:VKTX) while setting a price target at $89. This lea... Full story

Yahoo Finance • 21 days ago

Prediction: Eli Lilly Will Reach $1,200 in 2026

Eli Lilly (NYSE: LLY) doesn't need a perfect year to reach $1,200 in 2026. It does, however, need to maintain its continued dominance in the rapidly growing market for obesity and diabetes drugs -- and that's exactly how things are playing... Full story

Yahoo Finance • 22 days ago

GLP-1 Sales Forecast Jumps To $150 Billion By 2030

This article first appeared on GuruFocus. TD Cowen has lifted its global GLP-1 sales forecast to $150 billion by 2030, up from its prior $139 billion estimate issued just over a year ago, signaling that demand for the drug class populariz... Full story

Yahoo Finance • 24 days ago

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock

Key Points Eli Lilly and Novo Nordisk are much larger companies and already have oral weight loss pills on the market. Investors are hoping Viking's VK2735 will prove efficacious and safe in its Phase 3 clinical trials. 10 stocks we like... Full story

Yahoo Finance • 25 days ago

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

Key Points VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offer efficacy advantages over competitors' oral drugs.10 stocks we like better than... Full story

Yahoo Finance • 29 days ago

Eli Lilly's $1 trillion valuation cements its status as Wall Street's ultimate weight-loss play

Eli Lilly (LLY) is back above $1 trillion, closing at its first record high since November, as Wall Street starts pricing in a drug many investors may not know yet: Reta. The stock is up more than 25% since the market’s March 30 low and m... Full story

Yahoo Finance • last month

If Viking Therapeutics Is Acquired, Here’s Who Wins

Quick Read Viking Therapeutics (VKTX) is the most closely watched biotech acquisition target. A buyer such as Eli Lilly (LLY) would benefit, as would Viking shareholders, and at least one GLP-1 competitor. The analyst who called NVIDIA in... Full story

Yahoo Finance • last month

Is Viking Therapeutics a Top Takeover Target?

Viking Therapeutics(NASDAQ: VKTX) increasingly looks like an acquisition candidate in biotech. But why? It's because large pharmaceutical companies are desperate to secure obesity drug exposure, and Viking controls one of the more advance... Full story

Yahoo Finance • 2 months ago

Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And Loss

In late April 2026, Viking Therapeutics reported a wider first‑quarter net loss of US$158.33 million as research and development spending accelerated, while confirming that its Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials for VK2735 ar... Full story

Yahoo Finance • 2 months ago

Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?

Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by Charlie Evans PhD. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was... Full story

Yahoo Finance • 2 months ago

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB: AVAI), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Viking Therapeutics, Inc. (NASDAQ: VKTX), Longeveron Inc. (N... Full story

Yahoo Finance • 2 months ago

How CVS And Amazon Chipped Away At Eli Lilly, Novo Nordisk Stocks

Eli Lilly and Novo Nordisk stocks took a header Tuesday on reports CVS Health opted out of covering GLP-1s through Medicare. Continue Reading... Full story

Yahoo Finance • 2 months ago

Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon.

Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics tumbled Tuesday after Amazon.com announced it would sell weight-loss drugs. Continue Reading... Full story

Yahoo Finance • 2 months ago

Better Long-Term Buy: Eli Lilly or Viking Therapeutics?

Key Points Eli Lilly has been a growth beast, coming off an impressive year in which its revenue rose by 45%. Viking Therapeutics has an exciting GLP-1 drug in development that, if approved, could send its shares skyrocketing.10 stocks we... Full story

Yahoo Finance • 3 months ago

Is It Too Early To Consider Viking Therapeutics (VKTX) A Bargain After Recent Pullback?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. If you are wondering whether Viking Therapeutics at around US$34.26 is still offering value or is... Full story